Posts Tagged ‘AMD’
Stem Cell Therapies for AMD Making Strides
In 2013, the first clinical study of stem cells in ophthalmology set high hopes that companies may one day develop cell-based therapies for neovascular age-related macular degeneration (AMD). A recent spate of clinical and intellectual advances certainly hasn’t dampened anyone’s enthusiasm. Research scientists continue to focus on replacement therapy for the retinal pigment epithelium (RPE)…
Read MoreLudwin Monz, PhD, Discusses Zeiss, its Legacy & Where it Pursues New Innovation
Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec AG, shares how his company’s long history in ophthalmology helps it pave a path for new markets and technologies. Podcast Guest Ludwin Monz, PhD Dr. Ludwin Monz has been President and CEO of Carl Zeiss Meditec AG since 2010 and was appointed a member of…
Read MoreEye Care Priority for J&J
Ashley McEvoy, Company Chair of Vision Care and Diabetes at Johnson & Johnson, joins OISTV to discuss Johnson & Johnson’s commitment to eye health. Video Highlights 00:49 – Emerging areas of interest: lung cancer, diabetes and eye health? 01:00 – What areas in eye care are you looking at? 01:25 – How does expertise in…
Read MoreOISPodcast@ASCRS – Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 086″] Deals sometime collapse, but they usually don’t get hit with a smart bomb from the Department of Treasury. Allergan, newly single following the break up with Pfizer, is looking to build a business in ophthalmology. Bill Meury, the newly named chief commercial officer of Allergan, talks about the non-Pfizer deal,…
Read MoreGraybug Vision – Making Big Moves
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 084″] Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would use the capital to shift its approach from a drug delivery platform technology company to a drug maker. Ten…
Read MoreOutlook for Combination Therapies in Retinal Disease
When Regeneron Pharmaceuticals and Bayer announced their collaboration to develop and commercialize a combination therapy using Regeneron’s vascular endothelial growth factor (VEGF) trap aflibercept (Eylea) and its angiopoietin2 (ANG-2) antibody, nesvacumab, it was the latest in a rash of endeavors – at least seven at last count – to marry different compounds and anti-VEGF agents…
Read MoreKOL Corner: Can Complement Inhibitors Treat Macular Degeneration?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 080″] The complement system is a promising target for drugs being developed to treat macular degeneration. But success has been elusive. A leading KOL and two CEOs explain what the future of the field may be. Podcast Transcript Tom Salemi: Hi, everyone, welcome back to the OIS Podcast. This is your…
Read MoreWithout Pfizer Deal, Allergan Looks Ahead: Could B+L be in its Sights?
Now that Pfizer and Allergan have mutually agreed to terminate their proposed merger, Allergan CEO Brent Saunders told analysts Wednesday morning that the company is moving ahead with new product development, but he would not rule out the possibility of Allergan making a play for his old employer, Bausch + Lomb. The merger foundered when…
Read MoreCan Apellis Find a way to Inhibit the Complement System & Treat Intermediate AMD?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 078″] Clinical trials of complement inhibitors recently have produced some disappointing results, but Apellis remains committed to demonstrating its own inhibitor can help bring relief to people battling geographic atrophy and AMD. 10 Top Topics in this OIS Podcast: What’s this about a Face Transplant? A successful spinout from Potentia. How…
Read MoreWhat’s New with Three Sustained-Release Drug Platforms
Most ophthalmic drugs are delivered by topical application or direct injection into the vitreous, and many are limited by difficulties in sustaining therapeutic drug levels or by problems with patient adherence. As effective as topical drops are for delivering medication to the eye, they are wholly dependent on patient adherence. Even patients with potentially blinding…
Read MoreVisionCare Battling Back Against Macular Degeneration
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 076″] CEO Wolfgang Tolle joined VisionCare last year to move the company into the commercial stage. Now with long-term data and reimbursement in place, the firm is making a strong commercial push. Transcript Tom Salemi: Hello, OIS Podcast listeners, this is Tom Salemi, your host. Thanks for joining us today on…
Read MoreHeier Talks Anti-Angiopoietin Programs, Clinical Trials & Red Sox
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 075″] Jeff Heier, MD, is the Director of the Vitreoretinal Service and the Director of Retina Research at Ophthalmic Consultants of Boston (OCB) gives an update from the Angiogenesis conference about the advancing anti-angiopoietin programs. Podcast Guest Jeffrey Heier, MD Jeffrey S. Heier, MD is the Director of the Vitreoretinal Service…
Read More